A family of novel TEAD palmitoylation site inhibitors with exceptional pre-clinical anti-neoplastic activity as a monotherapy and in combination with MAPK inhibitors. (October 2022) - Muller, F.; Warshaviak, D.; Gyuris, J.; Nir, R.; Baloglu, E.; Shacham, S.; Morley, A.; Depinho, R.